Chickenpox
Therapeutic area
Dermatology
Rare disease
No
- Definition
- A contagious childhood disorder caused by the varicella zoster virus. It is transmitted via respiratory secretions and contact with chickenpox blister contents. It presents with a vesicular skin rash, usually associated with fever, headache, and myalgias. The pruritic fluid-filled vesicles occur 10-21 days after exposure and last for 3-4 days. An additional 3-4 days of malaise follows before the affected individual feels better. An individual is contagious 1-2 days prior to the appearance of the blisters until all blisters are crusted over. Generally, healthy individuals recover without complications.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Chickenpox
- Therapeutic area
- Dermatology
- chickenpox
- Varicella
- chicken pox
- chicken pox infection
- chickenpox
- varicella
- Disease mechanisms
- Acquired
- Severity
- Mild
- Dermatology
- Infectious Disease
- MONDO ID
- MONDO:0005700
- Parent condition
- MONDO:0005608
Related records
Broader conditions (14)
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Herpesviridae infectious disease
- Human disease
- Infectious disease
- Integumentary system disorder
- Primary viral infectious disease
- Skin disorder
- Skin disorder caused by infection
- Varicella zoster infection
- Vesiculobullous skin disease
- Viral infectious disease
Trials (167)
- A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines
- A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
- A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older
- A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
- A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine
- A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.
- A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years
- A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children
- A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
- A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
- A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
- A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
- A Study of ProQuad™ in Healthy Children in Korea (V221-023)
- A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
Approved drugs (3)
- Acyclovir
- Valacyclovir hydrochloride
- Varicella zoster virus, live attenuated
Drugs in development (2)
- Rubella virus vaccine live Phase 3
- Varicella-zoster immune globulin Phase 1
Other linked drugs (1)
- Valacyclovir